JP2024534935A5 - - Google Patents

Info

Publication number
JP2024534935A5
JP2024534935A5 JP2024514635A JP2024514635A JP2024534935A5 JP 2024534935 A5 JP2024534935 A5 JP 2024534935A5 JP 2024514635 A JP2024514635 A JP 2024514635A JP 2024514635 A JP2024514635 A JP 2024514635A JP 2024534935 A5 JP2024534935 A5 JP 2024534935A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
ephrin
ineffective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534935A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/042812 external-priority patent/WO2023039008A1/en
Publication of JP2024534935A publication Critical patent/JP2024534935A/ja
Publication of JP2024534935A5 publication Critical patent/JP2024534935A5/ja
Pending legal-status Critical Current

Links

JP2024514635A 2021-09-07 2022-09-07 エフリンｂ２発現を用いたがんの診断方法 Pending JP2024534935A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163241448P 2021-09-07 2021-09-07
US63/241,448 2021-09-07
PCT/US2022/042812 WO2023039008A1 (en) 2021-09-07 2022-09-07 Diagnostic methods for cancer using ephrinb2 expression

Publications (2)

Publication Number Publication Date
JP2024534935A JP2024534935A (ja) 2024-09-26
JP2024534935A5 true JP2024534935A5 (https=) 2025-09-24

Family

ID=85506954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514635A Pending JP2024534935A (ja) 2021-09-07 2022-09-07 エフリンｂ２発現を用いたがんの診断方法

Country Status (8)

Country Link
US (1) US20250123284A1 (https=)
EP (1) EP4398928A4 (https=)
JP (1) JP2024534935A (https=)
KR (1) KR20240053651A (https=)
CN (1) CN118510533A (https=)
AU (1) AU2022343102A1 (https=)
CA (1) CA3231533A1 (https=)
WO (1) WO2023039008A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025205534A1 (ja) * 2024-03-25 2025-10-02 積水メディカル株式会社 免疫測定方法、精度管理方法、標準試料及び免疫測定試薬

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101932604A (zh) * 2007-03-12 2010-12-29 瓦斯基因治疗公司 EphB4作为诊断标记和作为卵巢癌的治疗靶标的用途
AU2020241963A1 (en) * 2019-03-17 2021-11-04 Vasgene Therapeutics Inc Treatment of cancers using sEphB4-HSA fusion proteins

Similar Documents

Publication Publication Date Title
CN108623685B (zh) 抗ox40抗体及其用途
CN115023227B (zh) 用于治疗癌症的PD-1拮抗剂、VEGFR/FGFR/RET酪氨酸激酶抑制剂和CBP/β-联蛋白抑制剂的组合
CN112794911B (zh) 人源化抗叶酸受体1抗体及其应用
TW201834696A (zh) 藉由投予抗her3抗體－藥物複合體之egfr－tki抗性之非小細胞肺癌的治療方法
TW201642897A (zh) Ｈｅｒ２結合劑治療
JP2021167324A5 (https=)
TW201620547A (zh) Ｐｄ－ｌ１陰性腫瘤之組合療法
JP2022519341A (ja) ヒトネクチン－２に特異的な抗体
JP2022525223A5 (https=)
CN105378479A (zh) 用于预测免疫疗法的临床效果的方法
JP2022525223A (ja) ｓＥｐｈＢ４－ＨＳＡ融合タンパク質を用いたがんの治療
JP2022520596A5 (https=)
JP2023541482A (ja) バイオマーカー法および使用法
CN113677707A (zh) 用于在治疗癌症中增强效力的il-4/il-13途径抑制剂
TW202246336A (zh) 藉由投予先導性ｐｄ－１抑制劑治療癌症之方法
JP2003511019A (ja) Ｉｌ１３変異体
JPWO2005071075A1 (ja) 上皮細胞増殖因子受容体（ｅｇｆｒ）由来ペプチド
JP2024534935A5 (https=)
TW202328212A (zh) Ｍａｇｅ—ａ４陽性癌症之治療
JP2025509183A (ja) がんの処置のためのｋｒａｓ阻害剤を含む併用療法
JP4452839B2 (ja) Ｃｘｃｒ３阻害剤を含有する医薬組成物
JP2022544307A (ja) Ｌｒｐ６タンパク質に結合する抗体および使用方法
US20250296966A1 (en) Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
CN121038817A (zh) 抗-b7-h3抗体-药物缀合物和atr抑制剂或atm抑制剂的组合
CN118373896A (zh) 抗pd-1抗体与il-2突变体的双功能融合蛋白